Latest Conference Articles

March 10th 2014, 9:14am

PER® Miami Breast Cancer Conference

New models have emerged for examining novel breast cancer treatments in the neoadjuvant setting that avoid the lengthy process of standard, large adjuvant trials.

March 10th 2014, 8:59am

PER® Miami Breast Cancer Conference

In the last decade, there have been tremendous improvements in the treatment of HER2-positive breast cancer with new HER2-targeted agents improving survival in both the adjuvant and metastatic settings.

March 10th 2014, 8:46am

PER® Miami Breast Cancer Conference

The first-line combination of trastuzumab and eribulin mesylate demonstrated an ORR of 71.2% with a median PFS of 11.6 months in patients with HER2-positive advanced breast cancer.

March 10th 2014, 7:22am

PER® Miami Breast Cancer Conference

Ellen T. Matloff, MS, CGC, director, Yale Cancer Genetic Counseling Program at the Yale School of Medicine/Yale Cancer Center, discusses the proper age for a carrier of the BRCA1 or BRCA2 mutation to undergo oophorectomy.

March 8th 2014, 1:46pm

PER® Miami Breast Cancer Conference

Sunil Verma, MD, MSEd, FRCPC, associate professor, University of Toronto, chair, Breast Medical Oncology, Sunnybrook Odette Cancer Centre, provides an outlook on the treatment of HER2-positive breast cancer.

March 8th 2014, 10:54am

PER® Miami Breast Cancer Conference

Success rates for lumpectomies or mastectomies are high with respect to survival, with up to 98% long-term survival rates for surgery and/or radiotherapy, but what if similar results could be achieved by substituting targeted medications for therapy?

March 8th 2014, 9:00am

PER® Miami Breast Cancer Conference

The US Supreme Court's landmark decision last June, mandating that an individual's genes cannot be patented, transformed the genetic testing landscape and opened the marketplace to a host of new and complicated testing options.

March 8th 2014, 8:19am

PER® Miami Breast Cancer Conference

The most promising novel therapeutics in development for patients with breast cancer focus primarily on targeting activating mutations in combinations that are based on findings from next-generation sequencing.

March 7th 2014, 12:47pm

PER® Miami Breast Cancer Conference

Debu Tripathy, MD, co-leader, Women's Cancer Program, University of Southern California Norris Comprehensive Cancer Center, discusses using adjuvant bisphosphonates as a treatment option for patients with breast cancer.

March 7th 2014, 12:44pm

PER® Miami Breast Cancer Conference

Judy C. Boughey, MD, associate professor of surgery, director, Breast Surgical Oncology Training Program, Mayo Clinic, discusses surgical resection of the primary breast tumor in patients with stage IV breast cancer.

March 7th 2014, 9:54am

PER® Miami Breast Cancer Conference

Since its approval in 1998 to treat metastatic breast cancer, the anti-HER2 monoclonal antibody trastuzumab has dramatically expanded life expectancy and improved quality of life for women diagnosed with HER2-positive disease.

March 7th 2014, 8:59am

PER® Miami Breast Cancer Conference

Over the past few decades, the optimal margin width for minimizing recurrence after breast-conserving surgery (BCS; lumpectomy) has been a topic of much debate

March 7th 2014, 8:27am

PER® Miami Breast Cancer Conference

The large Canadian study that has caused a stir by indicating that mammograms are of no use in women aged 40 to 59 years, and in fact can lead to over-diagnosis of breast cancer, is flawed and misleading

March 6th 2014, 3:46pm

PER® Miami Breast Cancer Conference

Melvin J. Silverstein, MD, FACS, director, Breast Program Hoag Memorial Hospital, professor of surgery, Keck School of Medicine, University of Southern California, describes oncoplastic surgery.

March 6th 2014, 12:35pm

PER® Miami Breast Cancer Conference

Hyman B. Muss, MD, discusses optimizing the administration of endocrine therapies with or without mTOR inhibitors for patients with HR-positive metastatic breast cancer

February 3rd 2014, 12:36pm

Genitourinary Cancers Symposium (ASCO GU)

Tomasz Beer, MD, FACP, professor of Medicine, deputy director of the Knight Cancer Institute, Oregon Health and Science University, discusses the treatment of metastatic castration-resistant prostate cancer (mCRPC) with abiraterone and enzalutamide as it relates to results from the PREVAIL study.

February 3rd 2014, 11:05am

Genitourinary Cancers Symposium (ASCO GU)

Sophie D. Fosså, MD, PhD, professor, Department of Oncology, Oslo University Hospital, Norway, discusses a trial analyzing the benefit for radiotherapy/antiandrogen combination in men with locally advanced prostate cancer.

February 3rd 2014, 10:22am

Genitourinary Cancers Symposium (ASCO GU)

High tumor expression of the protein PD-L1 is independently associated with shorter OS in patients with mRCC receiving treatment with VEGF-targeted therapy.

February 1st 2014, 11:13am

Genitourinary Cancers Symposium (ASCO GU)

Two new combinations demonstrated activity in refractory or advanced, previously untreated urothelial carcinoma in phase II evaluations.

February 1st 2014, 11:04am

Genitourinary Cancers Symposium (ASCO GU)

Robert Figlin, MD, FACP, discusses updated data on the ADAPT trial, which is an ongoing international phase III randomized trial of autologous dendritic cell immunotherapy (AGS-003) plus standard treatment in metastatic renal cell carcinoma (mRCC)